CASE REPORT

Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy

Elisa Meucci | Anna Radice | Filippo Fassio | Maria Loredana Chiara Iorno | Donatella Macchia

Allergy and Clinical Immunology Unit, San Giovanni di Dio Hospital, Florence, Italy

Correspondence
Filippo Fassio, SOC Allergologia e Immunologia Clinica, Nuovo Ospedale San Giovanni di Dio, 50143 Florence, Italy.
Email: filippo.fassio@uslcentro.toscana.it

Funding information
Publication fees were covered by an unrestricted grant by Novartis Farma S.p.A, Largo U. Boccioni 1 – 21040 Origgio (VA), Italy

1 | INTRODUCTION AND BACKGROUND

Mosquito allergy can rarely give rise to severe clinical manifestations. Here, we describe the case of a patient suffering from relapsing anaphylaxis after mosquito bites, who completely responded to off-label therapy with anti-IgE monoclonal antibody. This is the first demonstration of the efficacy of omalizumab in such unusual life-threatening allergy.

Several immune mediated disorders are triggered by mosquito bites (Table 1).¹,² All of these are quite uncommon, including mosquito allergy. In this latter case, sensitized individuals usually develop immediate or delayed large local reactions, but in exceptional circumstances anaphylactic episodes have been described.³

Mosquitoes belong to the order Diptera, family Culicidae, which consists of three subfamilies, namely Toxorhynchitinae, Anophelinae and Culicinae. In Italy, three main mosquito species have been detected: common mosquito (Culex pipiens), tiger mosquito (Aedes albopictus) and the newly emerged korean mosquito (Aedes koreicus); Anopheles mosquito is also present but it rarely bites humans.⁴

To date, studies conducted primarily on Aedes aegypti (the yellow fever mosquito), which is present in tropical, subtropical and temperate regions throughout the world, identified a total of 22 salivary allergens and only four body allergens, including a tropomyosin (Aed a 7); among them, Aed a 1, Aed a 2 and Aed a 4 are potentially genuine allergens⁵

Moreover, the mosquito hyaluronidase has been identified as cross-reactive with that of wasp’s venom, giving rise to the so-called wasp/mosquito syndrome,⁶ and a recent study correlates mosquito (Aedes communis) and bee allergy.⁷

In most cases, mosquito allergy is due to the presence of saliva-specific IgE, and mosquitoes’ saliva has been confirmed as the main allergen source.⁸ Even

Abstract
Anaphylaxis after mosquito bite is rare, but life threatening. No approved preventive therapy is available to date, but omalizumab could be a promising therapeutic option for reducing risk and improving quality of life in these patients.

KEYWORDS
anaphylaxis, mosquito allergy, omalizumab
more uncommonly, hypersensitivity reactions can take place in sensitized individuals after inhalation of suspended allergens derived from mosquitoes’ bodies and emanations.3

The prolonged exposure to mosquitoes’ bites seems to be protective against the risk of developing hypersensitivity, due to a natural desensitization process; in these cases, mosquitoes’ specific IgE levels could increase but together with specific IgG1 and IgG4.9 Hence, mosquito allergy is more frequent in children than in adults.

The few existing studies regarding mosquito venom immunotherapy (VIT) are limited to little groups and have used whole-body extracts.10-13

Their results were promising, even though their primary endpoint was reduction of local reactions and eventually even respiratory symptoms, that could depend, as previously mentioned, on mosquito body allergens.10,11 Two subjects who developed anaphylaxis after mosquito bite were given mosquito VIT using mosquito body extracts: complete resolution was achieved in just one of them.14

Of interest, vaccines against mosquito salivary proteins have been tested to protect against mosquito-borne disease rather than allergies. The interaction of the host with saliva of vectors (in this case, mosquitoes) seems to favor the transmission of pathogens; the efficacy of such vaccines could deeply change the approach of preventing severe infectious diseases.15

On the other hand, interest toward mosquito allergy gradually faded over time, both from a scientific and pharmaceutical point of view, so that today VIT products for mosquito allergy are not commercially available anymore.

Even if less than thirty cases of anaphylaxis to mosquito bites have been reported to date worldwide,6,14,16-19 management of risk and quality of life (QoL) is exceedingly challenging in these patients.

### 2 | CASE REPORT

Here, we report the case of a 51-year-old man, living in Tuscany, Italy (an endemic region for the presence of mosquitoes) who had already referred to our Unit and in whom VIT for Polistes dominula and Vespa crabro was started, after he had experienced two systemic reactions (grade III according to Muller et al).20

More recently, he experienced two anaphylactic episodes characterized by urticaria, presyncope and ascertained hypotension, during dinner outdoor in summertime. In both cases, he was admitted to the Emergency Department and was treated with intravenous corticosteroids and intramuscular epinephrine, with complete resolution of symptoms.

After a detailed medical history, the patient referred that both reactions took place just after receiving several mosquito bites, which previously provoked only large local reactions (LLRs). Therefore, mosquito allergy was suspected.

Skin prick tests for respiratory and food allergy proved negative. Since skin tests with mosquito extract are no longer available in Italy, specific IgE against Aedes communis were evaluated and resulted increased (0.53 kU/L, n.v. <0.35 kU/L, total IgE 300 kU/L, n.v. <100 kU/L; ImmunoCAP, ThermoFisher Scientific).

Of note, the allergen source of the mosquito ImmunoCAP kit is the insect whole body, instead of its saliva, and this could explain the weak positivity in our patient.

Therefore, the two anaphylactic episodes were interpreted as Mueller IV reactions to mosquito bites.

The allergologic workup included IgE against potential cross-reactive allergens such as tropomyosin and cross-reactive carbohydrate determinants, which gave negative results.

In the suspicion of a mast cell disorder, serum basal tryptase was evaluated and resulted within normal range;
a haematological consultation was performed but bone marrow biopsy was not indicated due to the low probability of a clonal mast cell disorder according to the REMA score (+1).21

The patient was advised to always carry two epinephrine autoinjectors; however, the potential risk of sudden severe allergic reactions to mosquito bites, along with the difficulty in avoiding them, had a major impact on his QoL.

Therefore, the need for a prophylactic therapy was considered, but its choice was challenging.

The effectiveness of antihistamines has been demonstrated in reducing itching, wheals and LLRs but not in preventing systemic reactions.22,23 An immunotherapy with mosquito extract was not feasible, since its evidence is weak10,11 and, anyway, it is no longer available.

In the absence of other therapeutic options, the patient started off-label therapy with the anti-IgE monoclonal antibody omalizumab, 300 mg subcutaneously every 4 weeks, from August to October 2020.

In this period, he received several mosquito bites without experiencing neither anaphylactic episodes nor mild hypersensitivity reactions.

Given the good result, the therapy was started again in March this year (March to October is the period considered more at risk for mosquito bites in Tuscany), without relapses to date. In parallel, the patient was able to resume outdoor activities and reported a significant reduction of psychological burden of disease.

3 | DISCUSSION

Venom immunotherapy has been defined as a disease modifying treatment, since it can target the pathogenic pathways of allergic response altering its natural history and inducing tolerance to allergens.24

In the case of Hymenoptera venom allergy, in which risk of anaphylaxis is elevated, VIT is responsible for a strong reduction of risk and a significant improvement in QoL.24

The lack of an immunotherapy for mosquito allergy, or other therapeutic options capable of reducing the risk of anaphylaxis for at-risk patients living in mosquito endemic area, could result in a failure of management of risk and QoL, as seen in other allergic conditions.25

Looking for other drugs targeting the underlying pathophysiology, anti-IgE monoclonal antibody was judged the most suitable choice.

Omalizumab is a recombinant humanized monoclonal anti-IgE antibody approved in Europe for the treatment of severe allergic asthma and chronic spontaneous urticaria refractory to standard therapies.26,27

Its efficacy is explained with the established omalizumab mechanism of action of binding free IgE and subsequent downregulation of FcεRI on mastcells, basophils, eosinophils and antigen presenting cells.27,28 Moreover, some Authors postulated an apoptotic effect of omalizumab on mastcells.29-31

Even if omalizumab use is off-label for this indication, it resulted capable of reducing incidence of anaphylaxis triggered by different allergens in clinical trials and real-life settings,32 and evidence is increasing in this regard.

In the context of food allergy, previous studies demonstrated that peanut allergic adults receiving omalizumab showed a 56-fold increase in the threshold challenge dose; in most cases, this change emerged early after the beginning of the treatment.33

When using omalizumab before and during peanut desensitization protocols, tolerance was achieved faster and to higher amounts of food compared to those receiving placebo.34

Its capacity in increasing the tolerability toward offending allergens has been demonstrated even in the context of Hymenoptera venom allergy. Those experiencing severe reactions during the build-up phase of Hymenoptera VIT did not relapse if premedicated with omalizumab,35-37 and this effect was confirmed also in patients with mast cell disorders.31,38

Moreover, omalizumab showed a favorable effect in reducing the risk of idiopathic anaphylaxis, even in the context of IgE-independent reaction and in patients with mast cell disorders.32,39-44

These subjects sometimes do not exhibit specific IgE against Hymenoptera venom nor positive skin tests despite life-threatening anaphylactic reactions. Since VIT is not indicated when venom hypersensitivity is not demonstrable, omalizumab was successfully used to mitigate relapsing episodes in two cases.39,40

In these studies, a quick achievement of protection was observed42 and the dosage of 300 mg/monthly was considered effective,41 while 150 mg every second week was associated with lower degree of protection.42

To date, there is no established protocol for the use of omalizumab in the prevention of anaphylaxis, especially regarding dosage. However, based on the aforementioned publications, in our patient we chose a dosage of 300 mg every 4 weeks, which proved effective in guaranteeing a protective effect against anaphylaxis episodes after mosquito bite.

Although a therapy with omalizumab in preventing severe allergic reactions after mosquito bite in a mastocytosis patient was already proposed by Reiter et al.,16 to our knowledge this is the first reported case in which omalizumab was used and proved to be effective in relapsing anaphylaxis after mosquito bite.
CONFLICTS OF INTEREST
The Authors declare no other conflict of interests.

AUTHOR CONTRIBUTIONS
ME was in charge of clinical management, and all the authors contributed to manuscript preparation and critical revision.

ETHICAL APPROVAL
Written informed consent was obtained from the patient.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Filippo Fassio https://orcid.org/0000-0002-0732-9090

REFERENCES
1. Crisp HC, Johnson KS. Mosquito allergy. Ann Allergy Asthma Immunol. 2013;110(2):65-69. https://doi.org/10.1016/j.anai.2012.07.023
2. Kimura H, Cohen JI. Chronic active Epstein-Barr virus disease. Front Immunol. 2017;8:1-6. https://doi.org/10.3389/fimmu.2017.01867
3. Cantillo JF, Fernández-Caldeas E, Puerta L. Immunological aspects of the immune response induced by mosquito allergens. Int Arch Allergy Immunol. 2014;165(4):271-282. https://doi.org/10.1159/000371349
4. Quanti e quali tipi di zanzare esistono in Italia? Accessed June 4, 2021. https://www.greene.me/vivere/salute-e-benessere/tipi-zanzare-esistenti-italia/
5. Cantillo JF, Puerta L, Lafosse-Marin S, Subiza JL, Caraballo L, Fernández-Caldeas E. Identification and characterization of IgE-binding tropomyosins in Aedes aegypti. Int Arch Allergy Immunol. 2016;170(1):46-56. https://doi.org/10.1159/000447298
6. Sabbah A, Hassoun S, Drouet M, Laurent MG, Doucet M. The wasp/mosquito syndrome. Allerg Immunol (Paris). 1999;31(6):175-184. http://www.ncbi.nlm.nih.gov/pubmed/10443298
7. Scala E, Pirrotta L, Uasuf CG, et al. Aedes communis reactivity is associated with bee venom hypersensitivity: an in vitro and in vivo study. Int Arch Allergy Immunol. 2018;176(2):101-105. https://doi.org/10.1159/000488866
8. Peng Z, Beckett AN, Engler RJ, Hoffman DR, Ott NL, Simons FER. Immune responses to mosquito saliva in 14 individuals with acute systemic allergic reactions to mosquito bites. J Allergy Clin Immunol. 2004;114(5):1189-1194. https://doi.org/10.1016/j.jaci.2004.08.014
9. Palosuo K, Brummer-Korvenkontio H, Mikkola J, Sahi T, Reunala T. Seasonal increase in human IgE and IgG4 antisaliva antibodies to aedes mosquito bites. Int Arch Allergy Immunol. 1997;114(4):367-372. https://doi.org/10.1159/000237696
10. Ariano R, Panzani RC. Efficacy and safety of specific immunotherapy to mosquito bites. Eur Ann Allergy Clin Immunol. 2004;36(4):131-138. http://www.ncbi.nlm.nih.gov/pubmed/15180354
11. Srivastava D, Singh BP, Sudha VT, Arora N, Gaur SN. Immunotherapy with mosquito (Culex quinquefasciatus) extract: a double-blind, placebo-controlled study. Ann Allergy Asthma Immunol. 2007;99(3):273-280. https://doi.org/10.1016/S1081-1206(10)60664-3
12. Manrique MA, González-Díaz S, Arias-Cruz A, et al. Efficacy of immunotherapy with allergenic extract of Aedes aegypti in the treatment of large local reaction to mosquito bites in children. World Allergy Organ J. 2012;5:S147. https://doi.org/10.1097/01.WOX.0000411578.60734.e0
13. Benaim-Pinto C, Fassrainer A. Intradermal immunotherapy in children with severe skin inflammatory reactions to Aedes aegypti and Culex quinquefasciatus mosquito bites. Int J Dermatol. 1990;29(8):600-601. https://doi.org/10.1111/j.1365-4362.1990.tb03479.x
14. McCormack DR, Salata HF, Hershey JN, Carpenter GB, Engler RJ. Mosquito bite anaphylaxis: Immunotherapy with whole body extracts. Ann Allergy. 1995;74(1):39-44.
15. Manning JE, Oliveira F, Coutinho-Abreu IV, et al. Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial. Lancet. 2020;395(10242):1998-2007. https://doi.org/10.1016/S0140-6736(20)31048-5
16. Reiter N, Reiter M, Altrichter S, et al. Case Report Anaphylaxis caused by mosquito allergy in systemic mastocytosis. Lancet. 2013;382(9901):1380. https://doi.org/10.1016/S0140-6736(13)61605-0
17. Galindo PA, Gómez E, Borja J, et al. Mosquito bite hypersensitivity. Allerg Immunopathol (Madrid). 1998;26(5):251-254. http://www.ncbi.nlm.nih.gov/pubmed/9885733
18. García Ortíz JC, Cosmes MP. Anaphylaxis from a mosquito bite. Med Clin (Barc). 1994;102(4):157. http://www.ncbi.nlm.nih.gov/pubmed/7907159
19. Hassoun S, Drouet M, Sabbah A. Anaphylaxis caused by a mosquito: 2 case reports. Allerg Immunol (Paris). 1999;31(8):285-287. http://www.ncbi.nlm.nih.gov/pubmed/10572584
20. Mueller HL. Further experiences with severe allergic reactions to insect stings. N Engl J Med. 1959;261(8):374-377. https://doi.org/10.1056/nejm195908202610803
21. Bonadonna P, Lombardo C, Zanotti R. Mastocytosis and Allergic Diseases. Vol 24.; 2014. Accessed November 1, 2018. http://www.jiaci.org/issues/vol24issue5/1.pdf
22. Kärppinen A, Brummer-Korvenkontio H, Petman L, Kautiainen H, Hervé JP, Reunala T. Levocetirizine for treatment of immediate and delayed mosquito bite reactions. Acta Derm Venereol. 2006;86(4):329-331. https://doi.org/10.2340/00015555-0085
23. Kärppinen A, Brummer-Korvenkontio H, Reunala T, Izquierdo I. Rupatadine 10 mg in the treatment of immediate mosquito-bite allergy. J Eur Acad Dermatology Venereol. 2012;26(7):919-922. https://doi.org/10.1111/j.1468-3083.2012.04543.x
24. Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy Eur J Allergy Clin Immunol. 2018;73(4):744-764. https://doi.org/10.1111/all.13262
25. Knibb RC, Huisssoon AP, Baretto R, et al. “It’s not an illness, it’s just bad luck”: The impact of anaphylaxis on quality of life in adults. Clin Exp Allergy. 2019;49(7):1040-1046. https://doi.org/10.1111/cea.13410
26. Licari A, Marseglia G, Castagnoli R, Marseglia A, Ciprandi G. The discovery and development of omalizumab for the treatment of asthma. Expert Opin Drug Discov. 2015;10(9):1033-1042. https://doi.org/10.1517/17460441.2015.1048220

27. Maurer M, Rosén K, Hsieh H-J, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924-935. https://doi.org/10.1056/NEJMoa1215372

28. Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72(4):519-533. https://doi.org/10.1111/all.13083

29. Lam V, Kalesnikoff J, Lee CWK, et al. IgE alone stimulates mast cell adhesion to fibronectin via pathways similar to those used by IgE + antigen but distinct from those used by Steel factor. Blood. 2003;102(4):1405-1413. https://doi.org/10.1182/blood-2002-10-3176

30. Kalesnikoff J, Huber M, Lam V, et al. Monomeric IgE stimulates mast cell adhesion to fibronectin via pathways similar to those used by IgE + antigen but distinct from those used by Steel factor. Immunity. 2001;14(6):801-811. https://doi.org/10.1016/S1074-7613(01)00159-5

31. Da Silva EN, Randall KL. Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome. J Allergy Clin Immunol Pract. 2013;1(6):687-688. https://doi.org/10.1016/j.jaip.2013.07.004

32. Carter MC, Marc I, Brittain EH, et al. A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis. J Allergy Clin Immunol. 2021;147(3):1004-1010.e2. https://doi.org/10.1016/j.jaci.2020.11.005

33. Savage JH, Courneya JP, Sterba PM, Macglashan DW, Saini SS, Wood RA. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol. 2012;130(5): https://doi.org/10.1016/j.jaci.2012.05.039

34. MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017;139(3):873-881.e8. https://doi.org/10.1016/j.jaci.2016.08.010

35. Palgan K, Bartuzi Z, Gotz-Zbikowska M. Treatment with a combination of omalizumab and specific immunotherapy for severe anaphylaxis after a wasp sting. Int J Immunopathol Pharmacol. 2014;27(1):109-112. https://doi.org/10.1177/03943201402700114

36. Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab.

J Investig Allergol Clin Immunol. 2009;19(3):225-229. http://www.ncbi.nlm.nih.gov/pubmed/19610266

37. Ricciardi L. Omalizumab: a useful tool for inducing tolerance to bee venom immunotherapy. Int J Immunopathol Pharmacol. 2016;29(4):726-728. https://doi.org/10.1177/039432016670920

38. Günsen A, Ruff F, Jappe U. Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis. Allergol Sel. 2021;5(01):128-132. https://doi.org/10.5414/alx02196e

39. Kontou-Fili K, Filis CI, Voulgari C, Panayiotidis PG. Omalizumab monotherapy for bee sting and unprovoked “anaphylaxis” in a patient with systemic mastocytosis and undetectable specific IgE. Ann Allergy Asthma Immunol. 2010;104(6):537-539. https://doi.org/10.1016/j.anai.2010.04.011

40. Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol. 2007;119(6):1550-1551. https://doi.org/10.1016/j.jaci.2007.03.032

41. Broesby-Olsen S, Vestergaard H, Mortz CG, et al. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. Allergy Eur J Allergy Clin Immunol. 2018;73(1):230-238. https://doi.org/10.1111/ael.13237

42. Lemal R, Fouquet G, Terriou L, et al. Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. J Allergy Clin Immunol Pract. 2019;7(7):2387-2395.e3. https://doi.org/10.1016/j.jaip.2019.03.039

43. Sanchez-Valenzuela MC, Garcia-Saucedo JC, Motoa G, Carrillo-Martin I, Gonzalez-Estrada A. Treatment of idiopathic anaphylaxis with omalizumab. Ann Allergy Asthma Immunol. 2019;123(6):612-613. https://doi.org/10.1016/j.anai.2019.09.020

44. Bilò MB, Martini M, Tontini C, Mohamed OE, Krishna MT. Idiopathic anaphylaxis. Clin Exp Allergy. 2019;49(7):942-952. https://doi.org/10.1111/cea.13402

How to cite this article: Meucci E, Radice A, Fassio F, Iorno MLC, Macchia D. Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy. Clin Case Rep. 2021;9:e04935. https://doi.org/10.1002/ccr3.4935